Catechol-O-methyltransferase inhibitor

Levodopa_metabolism_2.png

Catechol-O-methyltransferase inhibitor

Catechol-O-methyltransferase inhibitors (COMT inhibitors) are a class of medications that inhibit the action of the enzyme catechol-O-methyltransferase (COMT). This enzyme is involved in the breakdown of catecholamines, including important neurotransmitters such as dopamine, epinephrine, and norepinephrine. By inhibiting COMT, these medications increase the levels of these neurotransmitters in the brain and other tissues.

Mechanism of Action

COMT inhibitors work by blocking the activity of the COMT enzyme, which is responsible for the methylation and subsequent degradation of catecholamines. This inhibition leads to increased levels of dopamine and other catecholamines, which can be beneficial in conditions where these neurotransmitters are deficient.

Clinical Uses

COMT inhibitors are primarily used in the treatment of Parkinson's disease. They are often used in combination with levodopa and carbidopa to enhance the effectiveness of these medications. By preventing the breakdown of dopamine, COMT inhibitors help to prolong the action of levodopa, thereby improving motor symptoms in patients with Parkinson's disease.

Common COMT Inhibitors

Some of the commonly used COMT inhibitors include:

• Entacapone
• Tolcapone
• Opicapone

Side Effects

The use of COMT inhibitors can be associated with several side effects, including:

• Nausea
• Diarrhea
• Dyskinesia
• Hallucinations
• Hepatotoxicity (particularly with tolcapone)

Pharmacokinetics

COMT inhibitors are usually administered orally and have varying half-lives and durations of action. For example, entacapone has a relatively short half-life and is often taken multiple times a day, whereas opicapone has a longer half-life and can be taken once daily.

Research and Development

Ongoing research is focused on developing new COMT inhibitors with improved efficacy and safety profiles. Additionally, studies are being conducted to explore the potential use of COMT inhibitors in other neurological and psychiatric disorders.

See Also

• Parkinson's disease
• Levodopa
• Carbidopa
• Dopamine
• Neurotransmitter

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian